BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator- Changing Negative Cash Mentalities: Enabling Your Monetary Excursion
- Opening Your True capacity: 12 Techniques for Personal growth
- Coalition led by Iraqi PM al-Sudani wins parliamentary elections
- 10 Moving Design Frill for Summer 2023
- Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- Step by step instructions to Guarantee the Life span of Your Dental Inserts: Support and Care Guide
- Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- Launch pad damaged as Russian rocket blasts off for space station, agency says
